Orchard Therapeutics hires ex-PTC executive Mark Rothera as new CEO
A 2016 Fierce 15 winner and ultrarare disease startup Orchard Therapeutics has taken on Mark Rothera as its new president and chief.
Rothera, a near 30-year biopharma vet, comes to Orchard from controversial biotech PTC Therapeutics, where he served as its chief commercial officer. He’s also done stints as global president of Aegerion Pharmaceuticals, as well as VP and GM of commercial ops at Shire Human Genetic Therapies for the EMEA region.
Orchard is focused on ex vivo autologous hematopoietic stem cell gene therapy designed to restore normal gene function in primary immune deficiencies, metabolic diseases and hematological disorders.
This tech uses a sample of the patient’s own stem cells, which are modified with a functioning copy of the missing or faulty gene before being transplanted back into the patient’s body. Using the patient’s own cells (autologous) removes the need to search for a matching stem cell donor, which can take months or even years.Back to News